Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 20/20 | 1.00 |
| ▸ | MAPK3 | P27361 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 5/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | JAK1 | P23458 | 1/20 | 1.00 |
| ▸ | ZAP70 | P43403 | 1/20 | 1.00 |
| ▸ | JAK3 | P52333 | 1/20 | 1.00 |
| ▸ | TYRO3 | Q06418 | 1/20 | 1.00 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.60 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30189541 | 0.99 | SYK (0.98) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL19958390 | 0.92 | SYK (0.86) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL1354262 | 0.91 | SYK (1.00) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL14981713 | 0.91 | SYK (0.83) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL14975783 | 0.90 | SYK (0.82) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL14975885 | 0.90 | SYK (0.82) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL1355098 | 0.89 | SYK (1.00) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL1312569 | 0.89 | SYK (0.79) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL14975680 | 0.88 | SYK (0.78) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL16195116 | 0.86 | SYK (1.00) | SYKMAPK3MAPK1KCNH2AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 395 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186432-A1 | SPLEEN TYROSINE KINASE INHIBITOR, COMPOSITION, AND METHODS OF USE | PURDUE RESEARCH FOUNDATION | 2025-06-12 | — | — | US | claimed |
| WO-2025052354-A1 | SYK INHIBITORS FOR USE IN THE TREATMENT OF IMMUNE CHECKPOINT INHIBITION INDUCED ADVERSE EVENTS | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2025-03-13 | — | — | WO | claimed |
| EP-4520333-A1 | SYK INHIBITORS FOR USE IN THE TREATMENT OF IMMUNE CHECKPOINT INHIBITION INDUCED ADVERSE EVENTS | Albert-Ludwigs-Universität Freiburg (DE) | 2025-03-12 | — | — | EP | claimed |
| EP-4493188-A2 | SPLEEN TYROSINE KINASE INHIBITOR, COMPOSITION, AND METHODS OF USE | Purdue Research Foundation (US) | 2025-01-22 | — | — | EP | claimed |
| CN-119300822-A | Spleen tyrosine kinase inhibitors, compositions, and methods of use | 普渡研究基金会 | 2025-01-10 | — | — | CN | claimed |
| WO-2023178094-A2 | SPLEEN TYROSINE KINASE INHIBITOR, COMPOSITION, AND METHODS OF USE | PURDUE RESEARCH FOUNDATION (US) | 2023-09-21 | — | — | WO | claimed |
| EP-3191098-A1 | COMBINATIONS AND DOSING REGIMES TO TREAT RB-POSITIVE TUMORS | G1 Therapeutics, Inc. (US) | 2017-07-19 | — | — | EP | claimed |
| WO-2016040858-A1 | COMBINATIONS AND DOSING REGIMES TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | claimed |
| EP-2376481-B1 | PYRIMIDINECARBOXAMIDE DERIVATIVES AS INHIBITORS OF SYK KINASE | GLAXO GROUP LTD (GB) | 2013-08-07 | — | — | EP | claimed |
| EP-2376481-A1 | PYRIMIDINECARBOXAMIDE DERIVATIVES AS INHIBITORS OF SYK KINASE | Glaxo Group Limited (GB) | 2011-10-19 | — | — | EP | claimed |
| WO-2010097248-A1 | PYRIMIDINECARBOXAMIDE DERIVATIVES AS INHIBITORS OF SYK KINASE | GLAXO GROUP LIMITED (GB) | 2010-09-02 | — | — | WO | claimed |
| CN-122059926-A | Heterocyclic degradation determinants for target protein degradation | C4医药公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4735438-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735452-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20110275655-A1 | PYRIMIDINECARBOXAMIDE DERIVATIVES AS INHIBITORS OF SYK KINASE | GLAXO GROUP LIMITED (GB) | 2011-11-10 | — | — | US | disclosed |
| US-20110275655-A1 | PYRIMIDINECARBOXAMIDE DERIVATIVES AS INHIBITORS OF SYK KINASE | GLAXO GROUP LIMITED (GB) | 2011-11-10 | — | — | US | disclosed |
| EP-2376481-A1 | PYRIMIDINECARBOXAMIDE DERIVATIVES AS INHIBITORS OF SYK KINASE | Glaxo Group Limited (GB) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010097248-A1 | PYRIMIDINECARBOXAMIDE DERIVATIVES AS INHIBITORS OF SYK KINASE | GLAXO GROUP LIMITED (GB) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010097248-A1 | PYRIMIDINECARBOXAMIDE DERIVATIVES AS INHIBITORS OF SYK KINASE | GLAXO GROUP LIMITED (GB) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | SYK 4313/4885MAPK3 3406/4885MAPK1 4256/4885 |
| US-20250186432-A1 | SPLEEN TYROSINE KINASE INHIBITOR, COMPOSITION, AND METHODS OF USE | SYK, BTK, G6PD | SYK 1/4885MAPK3 285/4885MAPK1 873/4885 |
| US-20110275655-A1 | PYRIMIDINECARBOXAMIDE DERIVATIVES AS INHIBITORS OF SYK KINASE | SYK, KIT, LCK | SYK 1/4885MAPK3 770/4885MAPK1 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.